Structure-based design of a B cell antigen from B. pseudomallei.

Burkholderia pseudomallei is the etiological agent of melioidosis, a severe endemic disease in South-East Asia, causing septicemia and organ failure with high mortality rates. Current treatments and diagnostic approaches are largely ineffective. The development of new diagnostic tools and vaccines toward effective therapeutic opportunities against B. pseudomallei is therefore an urgent priority. In the framework of a multidisciplinary project tackling melioidosis through reverse and structural vaccinology, BPSL1050 was identified as a candidate for immunodiagnostic and vaccine development based on its reactivity against the sera of melioidosis patients. We determined its NMR solution structure and dynamics, and by novel computational methods we predicted immunogenic epitopes that once synthesized were able to elicit the production of antibodies inducing the agglutination of the bacterium and recognizing both BPSL1050 and B. pseudomallei crude extracts. Overall, these results hold promise for novel chemical biology approaches in the discovery of new diagnostic and prophylactic tools against melioidosis.

[1]  Matthew A. Kayala,et al.  A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens , 2009, Proceedings of the National Academy of Sciences.

[2]  M. Bolognesi,et al.  Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections , 2011, Proceedings of the National Academy of Sciences.

[3]  N. Ketheesan,et al.  Evidence of Burkholderia pseudomallei-Specific Immunity in Patient Sera Persistently Nonreactive by the Indirect Hemagglutination Assay , 2011, Clinical and Vaccine Immunology.

[4]  A. Cheng,et al.  The global distribution of Burkholderia pseudomallei and melioidosis: an update. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  Richard W Titball,et al.  Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis , 2011, BMC Microbiology.

[6]  Liisa Holm,et al.  Dali server: conservation mapping in 3D , 2010, Nucleic Acids Res..

[7]  Gert Vriend,et al.  CING: an integrated residue-based structure validation program suite , 2012, Journal of Biomolecular NMR.

[8]  R. Rappuoli,et al.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. , 2012, Vaccine.

[9]  G. Colombo,et al.  Peptides for immunological purposes: design, strategies and applications , 2013, Amino Acids.

[10]  Y. Suputtamongkol,et al.  Recent developments in laboratory diagnosis of melioidosis. , 2000, Acta tropica.

[11]  Michael Nilges,et al.  ARIA2: Automated NOE assignment and data integration in NMR structure calculation , 2007, Bioinform..

[12]  P. Aldhous Tropical medicine: Melioidosis? Never heard of it... , 2005, Nature.

[13]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[14]  A. Bax,et al.  TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts , 2009, Journal of biomolecular NMR.

[15]  X. Daura,et al.  Structural and Biochemical Characterization of NarE, an Iron-containing ADP-ribosyltransferase from Neisseria meningitidis* , 2011, The Journal of Biological Chemistry.

[16]  I. A. Grishina,et al.  The role of agglutination in bacterial infection , 2006, Bulletin of Experimental Biology and Medicine.

[17]  Wilfred F van Gunsteren,et al.  Biomolecular modeling: Goals, problems, perspectives. , 2006, Angewandte Chemie.

[18]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[19]  Nicholas J. White,et al.  Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei , 2006, Nature Reviews Microbiology.

[20]  R. Rappuoli,et al.  Structural vaccinology starts to deliver , 2012, Nature Reviews Microbiology.

[21]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[22]  B. Wren,et al.  Characterization of the Burkholderia pseudomallei K96243 Capsular Polysaccharide I Coding Region , 2012, Infection and Immunity.

[23]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[24]  Andrea J. Dowling,et al.  Novel gain of function approaches for vaccine candidate identification in Burkholderia pseudomallei , 2013, Front. Cell. Inf. Microbio..

[25]  G. Quilici,et al.  1H, 13C, 15N backbone and side chain NMR resonance assignments of BPSL1050 from Burkholderia pseudomallei , 2014, Biomolecular NMR assignments.

[26]  Rino Rappuoli,et al.  From empiricism to rational design: a personal perspective of the evolution of vaccine development , 2014, Nature Reviews Immunology.

[27]  T. Kodadek Chemical tools to monitor and manipulate the adaptive immune system. , 2014, Chemistry & biology.

[28]  Y. Gan Interaction between Burkholderia pseudomallei and the host immune response: sleeping with the enemy? , 2005, The Journal of infectious diseases.

[29]  Xavier Daura,et al.  Exploiting Antigenic Diversity for Vaccine Design , 2010, The Journal of Biological Chemistry.

[30]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[31]  N. Day,et al.  Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes , 2012, PLoS neglected tropical diseases.

[32]  Martin Zacharias,et al.  Prediction of protein-protein interaction sites using electrostatic desolvation profiles. , 2010, Biophysical journal.

[33]  R. Titball,et al.  Progress toward development of vaccines against melioidosis: A review. , 2010, Clinical therapeutics.

[34]  Alessandro Gori,et al.  A structure-based strategy for epitope discovery in Burkholderia pseudomallei OppA antigen. , 2013, Structure.

[35]  S. Puthucheary,et al.  Multiple-antigen ELISA for melioidosis - a novel approach to the improved serodiagnosis of melioidosis , 2013, BMC Infectious Diseases.

[36]  Alessandro Gori,et al.  Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. , 2013, Chemistry & biology.

[37]  J. Goldberg,et al.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei , 2008, Expert review of vaccines.

[38]  Giorgio Colombo,et al.  Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer , 2009, PLoS Comput. Biol..

[39]  Wayne Boucher,et al.  The CCPN data model for NMR spectroscopy: Development of a software pipeline , 2005, Proteins.

[40]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[41]  A. Cheng,et al.  Melioidosis: Epidemiology, Pathophysiology, and Management , 2005, Clinical Microbiology Reviews.

[42]  B. Drasar,et al.  Effects of Burkholderia pseudomallei and other Burkholderia species on eukaryotic cells in tissue culture. , 1998, Microbios.

[43]  S. Sirisinha Diagnostic value of serological tests for melioidosis in an endemic area. , 1991, Asian Pacific journal of allergy and immunology.

[44]  C. G. Bull THE AGGLUTINATION OF BACTERIA IN VIVO , 1915, The Journal of experimental medicine.

[45]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[46]  A. Pastore,et al.  Solution structure of the bacterial frataxin ortholog, CyaY: mapping the iron binding sites. , 2004, Structure.